Grazzini Grazia, Ciatto Stefano, Cislaghi Cesare, Castiglione Guido, Falcone Manuele, Mantellini Paola, Zappa Marco
ISPO Cancer Prevention and Research Institute Florence, Istituto Tumori Toscano, Viale A. Volta 171, 50131 Firenze, Italy.
J Med Screen. 2008;15(4):175-81. doi: 10.1258/jms.2008.008032.
To evaluate the direct costs of first and repeat colorectal cancer screening by immunochemical faecal occult blood testing (I-FOBT).
Florence district residents aged 50-70 were invited to undergo one-time I-FOBT every two years. Full colonoscopy was recommended for FOBT-positive subjects. Direct cost analysis was carried out separately for the first and repeat screening. All relevant resources consumed by the programme were calculated.
Among 25,428 or 62,369 subjects invited to the first or repeat screening, respectively, the corresponding participation rate was 47.8% or 52.3%, and the positivity rate was 4.4% and 3.3%. Corresponding detection rates and positive predictive values for cancer and advanced adenoma were 11.3% or 8.9% and 32.4% or 32.8%, respectively. The assessment phase accounted for the major cost, as compared with recruitment and screening. All cost indicators were slightly higher in the first screening compared with repeat screening. Cost per cancer and advanced adenoma detected was similar in the first or repeat screening. A higher than observed participation rate would have substantially reduced screening cost.
Analysis of I-FOBT-organized population-based screening cost demonstrates lower cost at repeat compared with first screening and provides reference for decision-making in screening implementation.
评估采用免疫化学法粪便潜血检测(I-FOBT)进行首次及重复结直肠癌筛查的直接成本。
邀请佛罗伦萨地区50至70岁的居民每两年接受一次I-FOBT检测。对FOBT检测呈阳性的受试者建议进行全结肠镜检查。分别对首次筛查和重复筛查进行直接成本分析。计算该项目消耗的所有相关资源。
在分别被邀请参加首次或重复筛查的25428名或62369名受试者中,相应的参与率分别为47.8%或52.3%,阳性率分别为4.4%和3.3%。癌症和高级别腺瘤的相应检出率和阳性预测值分别为11.3%或8.9%以及32.4%或32.8%。与招募和筛查相比,评估阶段占主要成本。首次筛查的所有成本指标均略高于重复筛查。首次或重复筛查中每检测出一例癌症和高级别腺瘤的成本相似。高于观察到的参与率将大幅降低筛查成本。
对I-FOBT组织的基于人群的筛查成本分析表明,重复筛查的成本低于首次筛查,并为筛查实施中的决策提供参考。